Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

and monitor disease progression. The xF+ assay integrates with the Tempus multimodal database, supporting therapeutic recommendations and clinical research. Originally introduced in 2022 ...